Mavacamten for Nonobstructive Hypertrophic Cardiomyopathy?

This safety study provides too little data for us to know despite the drug's promise in treating the obstructive phenotype.

Hypertrophic cardiomyopathy (HCM) can cause symptoms of heart failure, either from abnormal diastolic left ventricular (LV) function or from LV outflow obstruction in patients with the obstructive phenotype (oHCM). In a phase 2 study (NEJM JW Cardiol Jul 2019 and Ann Int Med 2019; 170:741), the non–FDA-approved reversible inhibitor of cardiac-specific myosin, mavacamten, substantially reduced LV outflow gradients in oHCM. Now, researchers report on a manufacturer-sponsored, placebo-controlled, dose-ranging, phase 2 trial assessing adverse events with mavacamten for symptomatic nonobstructive HCM (nHCM; MAVERICK-HCM; NCT03442764).

The study population comprised 58 individuals (mean age, 54; 58% women) with nHCM according to current guidelines…

Reviewing Author

Frederick A. Masoudi, MD, MSPH, FACC, FAHA

Disclosures

Consultant/Advisory BoardBristol Myers Squibb; CPC Clinical Research

Grant/Research SupportNational Heart, Lung, and Blood Institute

Editorial BoardsUpToDate; American College of Cardiology Self-Assessment Program (SAP)

Leadership Positions in Professional SocietiesAmerican College of Cardiology (Chair, Innovations Committee)